Trials / Completed
CompletedNCT01185301
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)
A Double-Blind, Randomized, Parallel-Arm, Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy With Adalimumab in Subjects With Early Rheumatoid Arthritis (CONCERTO)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 395 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adalimumab | Pre-filled syringe every other week |
| DRUG | methotrexate | weekly oral capsule dosing |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2010-08-19
- Last updated
- 2013-11-15
- Results posted
- 2013-11-15
Locations
68 sites across 10 countries: United States, Argentina, Austria, Belgium, Canada, Czechia, Germany, Poland, Puerto Rico, Spain
Source: ClinicalTrials.gov record NCT01185301. Inclusion in this directory is not an endorsement.